BR112016009962A2 - superagonistas de ação prolongada de hormônio glicoproteico - Google Patents

superagonistas de ação prolongada de hormônio glicoproteico

Info

Publication number
BR112016009962A2
BR112016009962A2 BR112016009962A BR112016009962A BR112016009962A2 BR 112016009962 A2 BR112016009962 A2 BR 112016009962A2 BR 112016009962 A BR112016009962 A BR 112016009962A BR 112016009962 A BR112016009962 A BR 112016009962A BR 112016009962 A2 BR112016009962 A2 BR 112016009962A2
Authority
BR
Brazil
Prior art keywords
glycoprotein hormone
acting
long
superagonists
treating
Prior art date
Application number
BR112016009962A
Other languages
English (en)
Inventor
D Weintraub Bruce
Szkudlinski Mariusz
Original Assignee
Trophogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trophogen Inc filed Critical Trophogen Inc
Publication of BR112016009962A2 publication Critical patent/BR112016009962A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

essa invenção fornece análogos de hormônios glicoproteicos superativos e de ação prolongada que demonstram bioatividade aumentada, tanto in vitro como in vivo, quando comparados com os seus homólogos de tipo selvagem. os análogos são particularmente úteis no tratamento de indivíduos com baixa expressão do receptor ou reatividade deficiente do receptor e para tratamento de qualquer condição associada à atividade de hormônios glicoproteicos.
BR112016009962A 2013-11-05 2014-11-05 superagonistas de ação prolongada de hormônio glicoproteico BR112016009962A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900094P 2013-11-05 2013-11-05
PCT/US2014/064143 WO2015069777A1 (en) 2013-11-05 2014-11-05 Glycoprotein hormone long-acting superagonists

Publications (1)

Publication Number Publication Date
BR112016009962A2 true BR112016009962A2 (pt) 2017-12-05

Family

ID=53042038

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016009962A BR112016009962A2 (pt) 2013-11-05 2014-11-05 superagonistas de ação prolongada de hormônio glicoproteico

Country Status (12)

Country Link
US (1) US10544200B2 (pt)
EP (1) EP3065766A1 (pt)
JP (1) JP2017502079A (pt)
KR (1) KR20160101906A (pt)
CN (1) CN105873602A (pt)
AR (1) AR098314A1 (pt)
AU (1) AU2014346859B2 (pt)
BR (1) BR112016009962A2 (pt)
CA (1) CA2929561A1 (pt)
MX (1) MX2016005973A (pt)
RU (1) RU2016117119A (pt)
WO (1) WO2015069777A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112136985B (zh) * 2020-09-27 2023-02-03 黑龙江省中医药科学院 一种提高鹅绒质量促进鹅绒增长的复合型饲料及其制备方法
CN115053865B (zh) * 2022-06-27 2023-04-14 四川省畜牧科学研究院 一种高产蛋鸡新品种的培育方法
CN116819103B (zh) * 2023-08-28 2023-11-07 成都大熊猫繁育研究基地 一种大熊猫tsh酶联免疫检测方法及单克隆抗体

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196123A (en) 1978-11-20 1980-04-01 Eugenia Rosemberg Hybrid chorionic gonadotropin preparations and methods for stimulating ovulation using same
DE3583528D1 (de) 1984-04-03 1991-08-29 Serono Lab Verfahren zur herbeifuehrung der ovulation.
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
ES2079345T3 (es) 1987-05-12 1996-01-16 Serono Pharm Praep Administracion subcutanea de gonadotropina corionica humana.
US5017566A (en) 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
AU4076589A (en) 1988-09-01 1990-04-02 Applied Research Systems Ars Holding N.V. Methods for producing gonadotropin and tsh super-agonists
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US6225449B1 (en) 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
EP0404458A3 (en) 1989-06-19 1992-03-04 Bunge (Australia) Proprietary Limited Ovine follicle stimulating hormone
WO1991016922A1 (en) 1990-05-08 1991-11-14 University Of Medicine & Dentistry Of New Jersey Analogs of glycoprotein hormones having altered immunological characteristics, efficacy and/or receptor specificity
ES2089227T3 (es) 1990-07-31 1996-10-01 Liposome Co Inc Acumulacion de aminoacidos y peptidos en el interior de liposomas.
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
JPH07507201A (ja) 1992-03-10 1995-08-10 ザ　ガバメント　オブ　ザ　ユナイテッド　ステイツ　オブ　アメリカ，アズ　レプリゼンテッド　バイ　ザ　セクレタリー，デパートメント　オブ　ヘルス　アンド　ヒューマン　サービシーズ 可変鋳型反応
US5604198A (en) 1994-05-12 1997-02-18 Poduslo; Joseph F. Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
US6020473A (en) 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
US6361992B1 (en) 1996-05-08 2002-03-26 The United States Of America As Represented By The Department Of Health And Human Services Thyroid stimulating hormone superagonists
JP3981413B2 (ja) 1996-05-08 2007-09-26 アメリカ合衆国 糖タンパク質ホルモンスーパーアゴニスト
DK1749836T3 (da) 1996-08-23 2009-08-31 Vegenics Ltd Rekombinant vaskulær endothelcellevækstfaktor D
EP0941310A1 (en) 1996-10-11 1999-09-15 THE TEXAS A&M UNIVERSITY SYSTEM Methods for the generation of primordial germ cells and transgenic animal species
US6750044B1 (en) 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
US6485942B1 (en) 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
US6080912A (en) 1997-03-20 2000-06-27 Wisconsin Alumni Research Foundation Methods for creating transgenic animals
US6281408B1 (en) 1998-02-20 2001-08-28 Thomas Jefferson University Efficient method for production of compound transgenic animals
WO2000017360A1 (en) 1998-09-22 2000-03-30 University Of Maryland, Baltimore Cystine knot growth factor mutants
WO2000025805A1 (en) 1998-11-02 2000-05-11 Ludwig Institute For Cancer Research Vascular endothelial growth factor-like protein from orf virus nz2 binds and activates mammalian vegf receptor-2
TWI277425B (en) 1999-04-13 2007-04-01 Lilly Co Eli Pulmonary administration of dry powder formulations for treating infertility
WO2000071713A1 (en) 1999-05-20 2000-11-30 Scios Inc. Vascular endothelial growth factor variants
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US20020127652A1 (en) 2000-02-11 2002-09-12 Schambye Hans Thalsgard Follicle stimulating hormones
AU2002317333C1 (en) 2001-08-01 2009-06-25 University Of Bristol VEGF isoform
WO2005042575A2 (en) 2003-10-30 2005-05-12 Pharmexa A/S Method for down-regulation of vegf
WO2005044851A1 (en) 2003-11-06 2005-05-19 Compugen Ltd. Variants of human glycoprotein hormone alpha chain: compositions and uses thereof
WO2005072417A2 (en) 2004-01-27 2005-08-11 The Ohio State University Research Foundation Vascular endothelial growth factors and methods of their use
AU2005223651B2 (en) 2004-03-19 2012-07-12 Trophogen, Inc. Follicle stimulating hormone superagonists
WO2011075606A2 (en) 2009-12-18 2011-06-23 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP3533874A1 (en) 2012-07-30 2019-09-04 Trophogen Inc. Glycoprotein hormone long-acting superagonists

Also Published As

Publication number Publication date
EP3065766A1 (en) 2016-09-14
CA2929561A1 (en) 2015-05-14
US10544200B2 (en) 2020-01-28
AR098314A1 (es) 2016-05-26
MX2016005973A (es) 2016-11-14
AU2014346859B2 (en) 2019-06-20
JP2017502079A (ja) 2017-01-19
AU2014346859A1 (en) 2016-05-12
KR20160101906A (ko) 2016-08-26
WO2015069777A1 (en) 2015-05-14
CN105873602A (zh) 2016-08-17
RU2016117119A (ru) 2017-12-11
US20160264639A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
NI201700042A (es) Composiciones y métodos de uso para tratar trastornos metabólicos.
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
CL2014003465A1 (es) Anticuerpo que se une al receptor del factor de crecimiento epidérmico humano dimérico (hegfr) ; composición farmacéutica que lo comprende; y uso para tratar el cáncer.
BR112017027132A2 (pt) reguladores do nrf2
CR20150296A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
PH12014502452A1 (en) Gip-glp-1 dual agonist compounds and methods
CL2014001994A1 (es) Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido.
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
MX2016008134A (es) Reguladores de nrf2.
MX2013015176A (es) Co-agonistas del receptor de glucagon/glp-1.
BR112012020558A2 (pt) moduladores do receptor de androgênio e seus usos
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
CO6660484A2 (es) Análogos de glucagón
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
BR112018006810A2 (pt) regimes de dosagem
BR112016022333A2 (pt) Sulfamidase modificada e produção da mesma
BR112016009962A2 (pt) superagonistas de ação prolongada de hormônio glicoproteico
NZ707016A (en) Glycoprotein hormone long-acting superagonists
CL2018001104A1 (es) Composición para el cuidado de la piel y procedimiento asociado.
PE20160121A1 (es) Formulaciones de factor viii recombinantes
BR112015024877A2 (pt) vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 4A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2486 DE 28-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI